advertisement
E-mail Page
Print Format
Google - Traducir esta página a español.
Google - Traduza esta página ao português.
 

  Back to Ask the Diabetes Team Ask the Diabetes Team
Question:

From Egg Harbor Township, New Jersey, USA:

I understand there is a new 24 hour long acting insulin which has just been approved for marketing by the FDA. It is Lantus Glargine, made by Hoechst. Will this be a better option than NPH or Ultralente for a 4 year old recently diagnosed Type 1 child? What are your thoughts on the new insulin, and when will it be available by prescription?

Answer:

Glargine is a new insulin analog that offers a very even release over the 24 hours after injection. Basically it is equivalent to two injections of NPH over the same period; but otherwise affords no striking improvement in control. It is likely to find a place in intensive insulin therapy where it is used with a Humalog dose after meals that is adjusted for the premeal blood sugar and appetite.

DOB

[Editor's comment: Insulin glargine is marketed by Aventis Pharmaceuticals under the brand name Lantus. JSH]

DTQ-20000427125351
Original posting 17 Jul 2000
Posted to Insulin

  
advertisement


 
Not Helpful  1 2 3 4 5  Very Helpful                  E-mail Article E-mail Page     Printer Friendly format Print Format    
  Home Return to Top

Last Updated: Tuesday April 06, 2010 15:09:11
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.

US Flag This site is published by Children With Diabetes, Inc, which is responsible for its contents.
By using this site, you agree to our Terms of Use, Legal Notice, Privacy Policy, and Safe Harbor Policy.
© Children with Diabetes, Inc. 1995-2013. Comments and Feedback.